Vimarsana
Biggest News Aggregation in the World

Page 30 - Cell Technologies News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cell Technologies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cell Technologies Today - Breaking & Trending Today

BD Selects "embecta" as Name of New Company for Planned Spinoff of Diabetes Care Business; Announces Remainder of Leadership Team - Vimarsana News

BD Selects "embecta" as Name of New Company for Planned Spinoff of Diabetes Care Business; Announces Remainder of Leadership Team

/PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that "embecta" [pronounced...

Flagship cancer therapy offers promise of potential side effects reduction - Vimarsana News

Flagship cancer therapy offers promise of potential side effects reduction

Medical technology company Terumo Blood and Cell Technologies and clinical-stage biotech Immunicom have signed a co-commercialisation agreement to advance a breast cancer therapy with potential to limit treatment–related adverse effects. Click to read more...

Mallinckrodt and Terumo Blood and Cell Technologies Announce Positive Recommendations in Australia for Public Funding of UVADEX® (methoxsalen) for ECP Administr - Vimarsana News

Mallinckrodt and Terumo Blood and Cell Technologies Announce Positive Recommendations in Australia for Public Funding of UVADEX® (methoxsalen) for ECP Administr

– In a dual-review process, two independent advisory committees to the Australian Minister for Health recommended reimbursement based on a...

Global Stem Cell Technologies Market is projected to be - Vimarsana News

Global Stem Cell Technologies Market is projected to be

Visiongain Published Global Stem Cell Technologies & Applications Market Report 2021-2031. Value Forecasts by Type (Allogenic, and Autologous), by...

Cell Therapy Market Research Report 2021: T Cells, CD34+ and/or CD133+ Stem Cells, Mesenchymal Stem/Stromal Cells are Predominantly Employed for Clinical Investigation - Vimarsana News

Cell Therapy Market Research Report 2021: T Cells, CD34+ and/or CD133+ Stem Cells, Mesenchymal Stem/Stromal Cells are Predominantly Employed for Clinical Investigation

/PRNewswire/ -- The "Global Cell Therapy Market Size, Share & Trends Analysis Report by Use-type, by Therapy Type (Autologous, Allogenic), by Region (North...